Cargando…
Advances in immunology. Volume 56
A Leader in Immunology.
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
San Diego ; New York ; Boston :
Academic Press,
�1994.
|
| Colección: | Advances in immunology.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Advances in Immunology, Volume 56; Copyright Page; Contents; Chapter 1. Properties and Functions of Interleukin-10; I. Introduction; II. Discovery; III. Physical Properties; IV. cDNA Cloning; V. Gene Structure; VI. Production; VII. Biological Effects of ILl0; VIII. Two Herpesviruses Have Acquired an ILl0 Gene; IX. Functional Similarities between ILl0 and Other TH2 Cytokines; X. Expression of ILl0 Correlates with TH2 Responses; XI. Effects of in Vivo Manipulation of ILl0 Levels; XII. ILl0 in Pregnancy; XIII. The ILl0 Receptor; XIV. Conclusions; References.
- Chapter 2. The Mechanism of V(D)J Joining: Lessons from Molecular, Immunological, and Comparative AnalysesI. Introduction; II. V(D)J Joining Basics; III. The Endogenous Substrate; IV. Model Systems; V. Fine-Structure of Recombinants: Clues to the Mechanism; VI. Agents of Joining; VII. The Origins of Order in V(D)J Joining; VIII. Fidelity and Pathogenesis; IX. The Joining Mechanism: A Working Hypothesis; X. Conclusion; Appendix; References; Chapter 3. Involvement of the Protein Tyrosine Kinase p56lck in T Cell Signaling and Thymocyte Development; I. Introduction.
- II. Regulation of lck ExpressionIII. Regulation of p56lck; IV. Signal Transduction via p56lck; V. Participation of p56lck in T Cell Signaling; VI. Involvement of p56lck in the Control of Thymocyte Development; VII. Future Directions; References; Chapter 4. Generating the Antibody Repertoire in Rabbit; I. Introduction; II. B Lymphocyte Development; III. Ig Genes and Gene Rearrangements; IV. Development of the Antibody Repertoire; V. GALT and the Antibody Repertoire; VI. Summary; References; Chapter 5. Immunotherapeutic Strategies Directed at the Trimolecular Complex; I. Introduction.
- II. Target 1: The T CellIII. Target 2: The Peptide Antigen; IV. Target 3: The MHC (la) Molecule; V. Conclusion; References; Chapter 6. Therapeutic Regulation of the Complement System in Acute Injury States; I. Introduction; II. An Overview of Complement Activation; III. Clinical Assessment of Complement Activation; IV. Intrinsic Regulation of Complement Activation; V. Interactions between Leukocytes and Complement; VI. Complement Deficiency States; VII. Clinical Injury and Acute Complement Activation (Failures of Intrinsic Regulation?); VIII. Therapeutic Complement Inhibition Using sCRl.
- IX. Therapeutic Complement Inhibition Using Other AgentsX. Summary; References; Chapter 7. Chemoimmunoconjugates for the Treatment of Cancer; I. Introduction: Concept of Targeted Chemotherapy; II. Monoclonal Antibodies as Carriers; III. Conjugation Chemistry; IV. Drug-Monoclonal Antibody Conjugates; V. Mode of Action of Drug-Monoclonal Antibody Conjugates; VI. Barriers to Antibody-Targeted Chemotherapy; VII. Clinical Trials; VIII. Conclusion; References; Chapter 8. The Molecular Basis of Susceptibility to Rheumatoid Arthritis; I. Overview; II. Objectives.